Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 22, 2009

NanoString’s Gene-Expression Technology to Be Used by NCI

  • The NCI has decided to use NanoString Technologies’ nCounter™ Analysis System at two of its core labs. The technology was selected based on the level of multiplexed gene-expression analysis it offers with high sensitivity and without the need for enzymes as well as its simple workflow. The nCounter Analysis System is composed of a fully automated sample-prep station, a digital analyzer, the CodeSet (molecular barcodes), and reagents needed to perform the analysis.

    One system was purchased by the NCI Center for Cancer Research (CCR)  and a second by SAIC-Frederick, operations and technical support contractor to NCI-Frederick. CCR investigators have already begun using the nCounter Analysis System in studies related to the mechanisms involved in cancer development. These include investigations into the role of inflammation in cancer and RNAi as well as studies measuring changes in gene expression in response to drug treatment.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »